---
title: "YONGAN PHARMACEUTICAL: The company's stock price is severely deviating from the market trend, posing a high risk of speculation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244573442.md"
description: "YONGAN PHARMACEUTICAL announced that its stock price has deviated from the market by more than 20% for two consecutive days on June 12 and 13, 2025, indicating a high risk of speculation. Although the stock price has risen significantly in the short term, the company's fundamentals have not undergone significant changes, and it is in a loss position for the first quarter of 2025"
datetime: "2025-06-15T09:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244573442.md)
  - [en](https://longbridge.com/en/news/244573442.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244573442.md)
generator: "portal-rs"
---

# YONGAN PHARMACEUTICAL: The company's stock price is severely deviating from the market trend, posing a high risk of speculation

According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL (002365.SZ) announced that the trading price of its stock on June 12, 2025, and June 13, 2025, had a cumulative closing price increase deviation exceeding 20% over two consecutive trading days, which constitutes an abnormal fluctuation in stock trading.

The announcement stated that the company's stock price had a significant short-term increase recently, which has seriously deviated from the overall market trend, posing a high risk of speculation. However, there has been no significant change in the company's fundamentals, and there is no undisclosed significant information that should be disclosed. In the first quarter of 2025, the company was in a loss position

### Related Stocks

- [002365.CN](https://longbridge.com/en/quote/002365.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [LEAD Launch Leaves Accountable Care Technology Buyers Little Time for a Wrong Decision, Q3 Study](https://longbridge.com/en/news/296106866.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**